IGI Laboratories, Inc., a NJ-based specialty generic pharmaceutical company, has entered into an agreement to acquire the assets of Alveda Pharmaceuticals, Inc. for $47 million in cash. Alveda is a Canadian generic pharmaceutical company focused on injectable pharmaceutical products that are supplied through Alveda’s long-term partnerships with European contract manufacturing organizations. Alveda currently markets 17 molecules in the Canadian market through its 36 injectables. Subject to ...